NAT2 and tuberculosis: The higher MAF of the NAT2 SNPs and the potential association of the SNPs and phenotype with AT-DILI reinforces the need for consideration of NAT2 pharmacogenomics as a potential preemptive biomarker for monitoring LFT and AT-DILI in TB treatment.